微信公众号

请长按图片识别二维码

模型资源

首页 模型资源 细胞资源 MC38-hCD39-LZ

Design of the MC38-hCD39-LZ cell line

The MC38 cell line was derived from C57BL/6 murine colon adenocarcinoma cells. They form solid tumors upon subcutaneous injection in immunocompetent mice.

We generated an MC38-hCD39-LZ clonal cell line expressing high levels of human CD39 (ENTPD1 NCBI GeneID: 953), and an optimized dual fusion reporter, luciferase-ZsGreen (LZ). MC38-hCD39-LZ cells form solid tumors in vivo. Isogenic luciferase-ZsGreen (LZ) cells are available.

This cell line can be used in syngeneic models with our hCD39 mouse model.

‍

MC38-hCD39-LZ features

  • Express a chimeric CD39, with a humanized extracellular domain
  • Express a luciferase-ZsGreen (LZ) fusion reporter
  • Form tumors upon subcutaneous injection in fully immunocompetent mice

  • MC38-hCD39-LZ cells homogeneously express human CD39 in vitro

    Expression analysis by flow cytometry. Human CD39 expression was assessed in MC38 parental cell line (grey) and MC38-hCD39-LZ cell line (red).

     

  • MC38-hCD39-LZ cells form infiltrated tumors in immunocompetent mice

    A. Humanized CD39 C57/Bl6 mice were injected (s.c.) with 1x106 MC38-hCD39-LZ cells. Tumor growth was measured every 2 to 4 days. Tumor size (mm3) = (width² x length)/2.
    B. Medium (200 mm3) and large (700 mm3) tumors were collected and tumor composition was determined by flow cytometry. Immune infiltrate = mCD45+; Non-immune cells, tumor cells = mCD45-.

Commentaries

  1. Development of a new hSIRPα-specific radiotracer for non-invasive PET imaging using genOway’s double humanized hCD47/hSIRPα mouse and MC38-hPD-L1-hCD47-LZ cell line
  2. CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity
  3. A new promising family of small molecules regulating the PD-L1/PD-1 signaling pathway
  4. Improving in vitro models: the coming of age of organoids
  5. iPS technology: Four factors that will change the world… some day

Scientific articles

  1. Two birds with one stone: human SIRPα nanobodies for functional modulation and in vivo imaging of myeloid cells
  2. CCX559 is a potent, orally-administered small molecule PD-L1 inhibitor that induces anti-tumor immunity
  3. ERα-36 regulates progesterone receptor activity in breast cancer
  4. T-cells expressing a chimeric-PD1-Dap10-CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer
  5. Tumor Vessel Normalization, Immunostimulatory Reprogramming, and Improved Survival in Glioblastoma with Combined Inhibition of PD-1, Angiopoietin-2, and VEGF
  6. SDHA gain-of-function engages inflammatory mitochondrial retrograde signaling via KEAP1-Nrf2